CSI Market
Sign In | Register

Bioventus Inc (BVS) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access BVS quarterly Cash Flow →
This cash flow overview for Bioventus Inc spans from Dec 31 2021 to Dec 31 2025, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income27.27
Depreciation & amortization47.01
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed1.26
Increase (Decrease) in Inventories8.57
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Business0.08
Share-based Compensation12.67
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), Unrealized-0.03
Profits Interest Plan Liability Classified And Other Equity Awards Compensation-
Derivative Gain Loss On Derivative Net-
Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest27.27
Change In Fair Value Of Equity Participation Rights-
Income taxes-0.91
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-0.92
Increase (Decrease) in Accounts Payable and Accrued Liabilities-19.81
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital-1.68
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-26.11
Discontinued operations0.00
Net Cash flow from Operating Activities74.67
Investing Activities
Capital Expenditures-2.56
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Proceeds From Payments For Acquisition Of Intangible Assets And Investments-
Payments To Acquire Businesses Held In Trust-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-0.69
Discontinued operations0.00
Net Cash Flow from Investing Activities-3.25
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-66.46
Long-term debt - borrowings76.91
Long-term debt - repayments-54.05
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock2.07
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-20.61
Proceeds From Members-
Payments To Members-
Distributions To Members-
Distributions Refunds To From Members-
Payment Of Debt Refinancing Costs-
Proceeds Form Deferred Consideration-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-62.14
Effect of exchange rate on cash flow0.37
Discontinued operations0.00
Free Cash Flow72.11
Total Cash Flow9.66
4 historic quarters locked

Sign in to unlock the full Bioventus Inc cash flow history.

Sign In Create Free Account

About Bioventus Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: March 5, 2026
  • Source: bvs-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001665988-26-000011

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License